High density lipoproteins and coronary heart disease. Future prospects in gene therapy

Biochimie

Volumn 80, Issue 2, 1998, Pages 167-172

  Fruchart, J C ^a   Duriez, P ^a  

^a INSERM   (France)

Author keywords

Apolipoprotein A I; Atherosclerosis; Gene therapy; High density lipoproteins; Lecithin cholesterol acyl transferase (LCAT); Transgenesis

Indexed keywords

APOLIPOPROTEIN A1; CHOLESTEROL ACYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE;

ADENOVIRUS; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; DIET; DYSLIPOPROTEINEMIA; EXPRESSION VECTOR; GENE THERAPY; GENE TRANSFER; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MOUSE; NONHUMAN; TRANSGENIC ANIMAL;

ADENOVIRIDAE; ANIMALIA; MUS MUSCULUS; ORYCTOLAGUS CUNICULUS;

EID: 0032005605     PISSN: 03009084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-9084(98)80023-0     Document Type: Article

References (21)

1. 1 Walsh A, Ifo Y, Breslow JL (l 989) High levels of humans apolipoprotein A-I in transgenic mice result in increased plasma levels of small high density lipoprotein (HDL) particles comparable to human HDL3. J Biol Chem 264, 6488-6494
2. 2 Rubin EM, Ishida BY, Clift SM, Krauss RM (1991) Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc Natl Acad Sci USA 88, 434-438
3. 3 Williamson R, Lee D, Hagaman J, Maeda N (1992) Marked reduction of high density lipoprotein cholesterol in mice genetically modify to lack apolipoprotein A-I. Proc Natl Acad Sci USA 89, 7134-7138
4. 4 Chajek-Shaul T, Hayek T, Walsh A, Breslow JL (1991) Expression of the human apolipoprotein A-I gene in transgenic mice alters high density lipoprotein (HDL) particle size distribution and diminishes selective uptake of HDL cholesteryl esters. Proc Natl Acad Sci USA 88, 6731-6735
5. 5 Schultz JR, Gorg EL, Mc Call MR, Nichols AV, Clift SM, Rubin EM (1992) Expression of human apolipoprotein A-II and its effect on high density lipoproteins in transgenic mice. J Biol Chem 267 (suppl 30), 21630-21636
6. 6 Schultz JR, Verstruyft JG, Gong EL, Nichols AV, Rubin EM (1993) Composition determines the anti-atherogenic properties of high density lipoproteins in transgenic mice. Nature 365, 761-764
7. 7 Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA (1987) Quantitative assessment of atherosclerosis lesions in mice. Atherosclerosis 68, 231-240
8. 8 Paigen B, Ishida BY, Verstruyft J, Winters R, Albeo D (1990) Atherosclerosis susceptibility differences among the progenitors of recombinant inbred strains of mice. Arteriosclerosis 10, 316-323
9. 9 Rubin EM, Krauss R, Spangler E, Verstruyft S, Clift S (1991) Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature 353, 265-267
10. 10 Plump AS, Scott CJ, Breslow JL (1994) Human apolipoprotein A-I gene expression increases high density lipoproteins and suppresses atherosclerosis in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA 91, 9607-9611
11. 11 Liu AC, Lawn RM, Verstruyft JG, Rubin EM (1994) Human apolipoprotein A-I prevents atherosclerosis associated with apolipoprotein (a) in transgenic mice. J Lipid Res 35, 2263-2267
12. 12 Duverger N, Viglietta C, Berthou L, Emmanuel F, Tailleux A, Parmentier-Nihoul L, Laine B, Fiévet C, Castro G, Fruchart JC, Houdebine LM, Denèfle P (1996) Transgenic rabbits expressing human apolipoprotien A-I in the liver. Arterioscler Thromb Vasc Biol 16, 1424-1429
13. 13 Duverger N, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, Castro G, Tailleux A, Fiévet C, Fruchart JC, Houdebine LM, Denèfle P (1996) Inhibition of atherosclerosis development in cholesterol-fed human apolipoprotein A-I transgenic rabbits. Circulation 94, 713-717
14. 14 Vaisman BL, Klein HG, Rouis M, Bérard AM, Kindt MR, Talley GD, Meyn SM, Hoyt RF, Marcovina SM, Albers JJ, Hoeg JM, Brewer B. Santamarina-Fojo S (1995) Overexpression of human lecithin cholesterol acyl transferase leads to hyperalphalipoproteinemia in transgenic mice. J Biol Chem 270, 12269-12275
15. 15 Hoeg JM, Vaisman BL, Demosky SJ, Meyn SM, Talley GD, Hoyt RF, Feldman S, Bérard AM, Sakai N, Wood D, Brouseau ME, Marcovina S, Brewer HB, Santamarina-Fojo S (1996) Lecithin: cholesterol acyl transferase overexpression generates hyperalphalipoproteinemia and a non atherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem 271, 4396-4402
16. 16 Brousseau ME, Santamarina-Fojo S, Zech LA, Bérard AM, Vaisman BL, Meyn SM, Powell D, Brewer HB, Hoeg JM (1996) Hyperalphalipoproteinemia in human lecithin cholesterol acyl transferase transgenic rabbits. In vivo apolipoprotein A-I catabolism is delayed in a gene dose-dependent manner. J Clin Invest 97, 1844-1851
17. 17 Hoeg JM, Santamarina-Fojo S, Bérard AM (1996) Overexpression of lecithin cholesterol acyl transferase in transgenic rabbits prevents diet-induced atherosclerosis. Proc Natl Acad Sci USA 93, 11448-11453
18. 18 Bérard AM, Föger B, Remaley A, Shamburek R, Vaisman BL, Talley G, Paigon B, Hoyt RF, Marcovina S, Brewer HB, Santamarina-Fojo S (1997) High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin cholesteryl acyl transferase. Nature Med 30, 744-749
19. 19 Föger B, Vaisman BL, Paigen B, Hoyt RJ, Brewer B, Santamarine-Fojo S (1997) CETP modulates the development of aortic atherosclerosis in LCAT transgenic mice. Circulation 96/8 (suppl) 108-116
20. 20 Koepfler W, Williard M, Betz, T, Willard JE, Gerard PD, Meidell RS (1994) Adenovirus-mediated transfer of a gene encoding human apolipoprotein A-I into normal mice increases circulating high density lipoprotein cholesterol. Circulation 90, 1319-1327
21. 21 Séguret-Macé S, Latta-Mahieu M, Castro G, Luc G, Fruchart JC, Rubin EM, Denèfle P, Duverger N (1996) Potential gene therapy for lecithin-cholesterol acyl transferase (LCAT) - deficient and hypoalphalipoproteinemic patients with adenovirus-mediated transfer of human LCAT gene. Circulation 94, 2177-2184